It is reported that currently, an industrial deployment with the Hangzhou medical port in Qiantang New District as the core and the
Hangzhou High-Tech Zone and Yuhang District as focuses has been realized
in the city.
The Hangzhou medical port in Qiantang New District will be built into a fastest-growing high-end biomedical product R&D cluster in
the city. The Hangzhou High-Tech Zone will focus on the construction of
the smart medical sector, while Yuhang District will focus on the
development of the medical equipment sector.
Based on the industrial deployment, an industrial structure featuring the R&D of new drugs, medical devices and medical data has
taken shape in the city, pushing up the continuous and fast growth of
the biomedical industry in Hangzhou.
Data showed that a cluster of more than 1,000 biomedical enterprises has already formed in the city. Besides, 1,003 biomedical firms were
newly set up in the city in 2018 with a registered capital of 8.569
billion yuan, up 39.11 % and 33.37 % year on year, respectively.
As the city boasts obvious advantages in developing the biomedical industry, currently, 88 companies with annual output value above 20
million yuan have gathered in Hangzhou, including 20-odd listed
companies. Seven of the global top ten pharmaceutical companies like
Pfizer, Merck Sharp & Dohme and Abbott have already settled in the
city.
Although Hangzhou is marching towards the upstream of the industrial chain, it is still lagged behind by Shanghai and Beijing in terms of
the development of the biomedical industry.
According to an official from the Hangzhou Investment Promotion Bureau, with the uneven development of the biomedical industry, Hangzhou
still needs to enhance its innovation capabilities and quicken the
construction of industrial ecology and the implementation of related
projects.
The development of important industrial platforms such as the Yangtze River Delta G60 sci-tech innovation corridor biomedical industry
alliance, as well as the integrated development of the Yangtze River
Delta, will all bring opportunities for the development of Hangzhou's
biomedical industry.
